Table of Content

1 Market Overview of Long-Acting Schizophrenia Drug
1.1 Long-Acting Schizophrenia Drug Market Overview
1.1.1 Long-Acting Schizophrenia Drug Product Scope
1.1.2 Long-Acting Schizophrenia Drug Market Status and Outlook
1.2 Global Long-Acting Schizophrenia Drug Market Size Overview by Region 2024 VS 2022 VS 2034
1.3 Global Long-Acting Schizophrenia Drug Market Size by Region (2024-2034)
1.4 Global Long-Acting Schizophrenia Drug Historic Market Size by Region (2024-2024)
1.5 Global Long-Acting Schizophrenia Drug Market Size Forecast by Region (2024-2034)
1.6 Key Regions, Long-Acting Schizophrenia Drug Market Size (2024-2034)
1.6.1 North America Long-Acting Schizophrenia Drug Market Size (2024-2034)
1.6.2 Europe Long-Acting Schizophrenia Drug Market Size (2024-2034)
1.6.3 Asia-Pacific Long-Acting Schizophrenia Drug Market Size (2024-2034)
1.6.4 Latin America Long-Acting Schizophrenia Drug Market Size (2024-2034)
1.6.5 Middle East & Africa Long-Acting Schizophrenia Drug Market Size (2024-2034)
2 Long-Acting Schizophrenia Drug Market by Type
2.1 Introduction
2.1.1 Oral
2.1.2 Injection
2.2 Global Long-Acting Schizophrenia Drug Market Size by Type: 2024 VS 2022 VS 2034
2.2.1 Global Long-Acting Schizophrenia Drug Historic Market Size by Type (2024-2024)
2.2.2 Global Long-Acting Schizophrenia Drug Forecasted Market Size by Type (2024-2034)
2.3 Key Regions Market Size by Type
2.3.1 North America Long-Acting Schizophrenia Drug Revenue Breakdown by Type (2024-2034)
2.3.2 Europe Long-Acting Schizophrenia Drug Revenue Breakdown by Type (2024-2034)
2.3.3 Asia-Pacific Long-Acting Schizophrenia Drug Revenue Breakdown by Type (2024-2034)
2.3.4 Latin America Long-Acting Schizophrenia Drug Revenue Breakdown by Type (2024-2034)
2.3.5 Middle East and Africa Long-Acting Schizophrenia Drug Revenue Breakdown by Type (2024-2034)
3 Long-Acting Schizophrenia Drug Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Pharmacies
3.1.3 Other
3.2 Global Long-Acting Schizophrenia Drug Market Size by Application: 2024 VS 2022 VS 2034
3.2.1 Global Long-Acting Schizophrenia Drug Historic Market Size by Application (2024-2024)
3.2.2 Global Long-Acting Schizophrenia Drug Forecasted Market Size by Application (2024-2034)
3.3 Key Regions Market Size by Application
3.3.1 North America Long-Acting Schizophrenia Drug Revenue Breakdown by Application (2024-2034)
3.3.2 Europe Long-Acting Schizophrenia Drug Revenue Breakdown by Application (2024-2034)
3.3.3 Asia-Pacific Long-Acting Schizophrenia Drug Revenue Breakdown by Application (2024-2034)
3.3.4 Latin America Long-Acting Schizophrenia Drug Revenue Breakdown by Application (2024-2034)
3.3.5 Middle East and Africa Long-Acting Schizophrenia Drug Revenue Breakdown by Application (2024-2034)
4 Long-Acting Schizophrenia Drug Competition Analysis by Players
4.1 Global Long-Acting Schizophrenia Drug Market Size by Players (2024-2024)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Long-Acting Schizophrenia Drug as of 2022)
4.3 Date of Key Players Enter into Long-Acting Schizophrenia Drug Market
4.4 Global Top Players Long-Acting Schizophrenia Drug Headquarters and Area Served
4.5 Key Players Long-Acting Schizophrenia Drug Product Solution and Service
4.6 Competitive Status
4.6.1 Long-Acting Schizophrenia Drug Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Johnson & Johnson
5.1.1 Johnson & Johnson Profile
5.1.2 Johnson & Johnson Main Business
5.1.3 Johnson & Johnson Long-Acting Schizophrenia Drug Products, Services and Solutions
5.1.4 Johnson & Johnson Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.1.5 Johnson & Johnson Recent Developments
5.2 Teva
5.2.1 Teva Profile
5.2.2 Teva Main Business
5.2.3 Teva Long-Acting Schizophrenia Drug Products, Services and Solutions
5.2.4 Teva Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.2.5 Teva Recent Developments
5.3 Eli Lilly
5.3.1 Eli Lilly Profile
5.3.2 Eli Lilly Main Business
5.3.3 Eli Lilly Long-Acting Schizophrenia Drug Products, Services and Solutions
5.3.4 Eli Lilly Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.3.5 Bristol Myers Squibb Recent Developments
5.4 Bristol Myers Squibb
5.4.1 Bristol Myers Squibb Profile
5.4.2 Bristol Myers Squibb Main Business
5.4.3 Bristol Myers Squibb Long-Acting Schizophrenia Drug Products, Services and Solutions
5.4.4 Bristol Myers Squibb Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.4.5 Bristol Myers Squibb Recent Developments
5.5 AstraZeneca
5.5.1 AstraZeneca Profile
5.5.2 AstraZeneca Main Business
5.5.3 AstraZeneca Long-Acting Schizophrenia Drug Products, Services and Solutions
5.5.4 AstraZeneca Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.5.5 AstraZeneca Recent Developments
5.6 Sumitomo Dainippon Pharma
5.6.1 Sumitomo Dainippon Pharma Profile
5.6.2 Sumitomo Dainippon Pharma Main Business
5.6.3 Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Products, Services and Solutions
5.6.4 Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.6.5 Sumitomo Dainippon Pharma Recent Developments
5.7 Allergan
5.7.1 Allergan Profile
5.7.2 Allergan Main Business
5.7.3 Allergan Long-Acting Schizophrenia Drug Products, Services and Solutions
5.7.4 Allergan Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.7.5 Allergan Recent Developments
5.8 Novartis
5.8.1 Novartis Profile
5.8.2 Novartis Main Business
5.8.3 Novartis Long-Acting Schizophrenia Drug Products, Services and Solutions
5.8.4 Novartis Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.8.5 Novartis Recent Developments
5.9 Cardinal Health
5.9.1 Cardinal Health Profile
5.9.2 Cardinal Health Main Business
5.9.3 Cardinal Health Long-Acting Schizophrenia Drug Products, Services and Solutions
5.9.4 Cardinal Health Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.9.5 Cardinal Health Recent Developments
5.10 Sun Pharmaceutical Industries
5.10.1 Sun Pharmaceutical Industries Profile
5.10.2 Sun Pharmaceutical Industries Main Business
5.10.3 Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Products, Services and Solutions
5.10.4 Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.10.5 Sun Pharmaceutical Industries Recent Developments
5.11 GlaxoSmithKline
5.11.1 GlaxoSmithKline Profile
5.11.2 GlaxoSmithKline Main Business
5.11.3 GlaxoSmithKline Long-Acting Schizophrenia Drug Products, Services and Solutions
5.11.4 GlaxoSmithKline Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.11.5 GlaxoSmithKline Recent Developments
5.12 Sanis Health
5.12.1 Sanis Health Profile
5.12.2 Sanis Health Main Business
5.12.3 Sanis Health Long-Acting Schizophrenia Drug Products, Services and Solutions
5.12.4 Sanis Health Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.12.5 Sanis Health Recent Developments
5.13 Qilu Pharmaceutical
5.13.1 Qilu Pharmaceutical Profile
5.13.2 Qilu Pharmaceutical Main Business
5.13.3 Qilu Pharmaceutical Long-Acting Schizophrenia Drug Products, Services and Solutions
5.13.4 Qilu Pharmaceutical Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.13.5 Qilu Pharmaceutical Recent Developments
5.14 Otsuka Pharmaceutical
5.14.1 Otsuka Pharmaceutical Profile
5.14.2 Otsuka Pharmaceutical Main Business
5.14.3 Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Products, Services and Solutions
5.14.4 Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.14.5 Otsuka Pharmaceutical Recent Developments
5.15 Vanda Pharmaceuticals
5.15.1 Vanda Pharmaceuticals Profile
5.15.2 Vanda Pharmaceuticals Main Business
5.15.3 Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Products, Services and Solutions
5.15.4 Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.15.5 Vanda Pharmaceuticals Recent Developments
5.16 H.Lundbeck
5.16.1 H.Lundbeck Profile
5.16.2 H.Lundbeck Main Business
5.16.3 H.Lundbeck Long-Acting Schizophrenia Drug Products, Services and Solutions
5.16.4 H.Lundbeck Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.16.5 H.Lundbeck Recent Developments
5.17 Organon
5.17.1 Organon Profile
5.17.2 Organon Main Business
5.17.3 Organon Long-Acting Schizophrenia Drug Products, Services and Solutions
5.17.4 Organon Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.17.5 Organon Recent Developments
5.18 Hansoh
5.18.1 Hansoh Profile
5.18.2 Hansoh Main Business
5.18.3 Hansoh Long-Acting Schizophrenia Drug Products, Services and Solutions
5.18.4 Hansoh Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.18.5 Hansoh Recent Developments
5.19 Hengrui
5.19.1 Hengrui Profile
5.19.2 Hengrui Main Business
5.19.3 Hengrui Long-Acting Schizophrenia Drug Products, Services and Solutions
5.19.4 Hengrui Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.19.5 Hengrui Recent Developments
5.20 Nhwa Group
5.20.1 Nhwa Group Profile
5.20.2 Nhwa Group Main Business
5.20.3 Nhwa Group Long-Acting Schizophrenia Drug Products, Services and Solutions
5.20.4 Nhwa Group Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.20.5 Nhwa Group Recent Developments
5.21 Yangtze River Pharmaceutical Group
5.21.1 Yangtze River Pharmaceutical Group Profile
5.21.2 Yangtze River Pharmaceutical Group Main Business
5.21.3 Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Products, Services and Solutions
5.21.4 Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Revenue (US$ Million) & (2024-2024)
5.21.5 Yangtze River Pharmaceutical Group Recent Developments
6 North America
6.1 North America Long-Acting Schizophrenia Drug Market Size by Country (2024-2034)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Long-Acting Schizophrenia Drug Market Size by Country (2024-2034)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Long-Acting Schizophrenia Drug Market Size by Region (2024-2034)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Long-Acting Schizophrenia Drug Market Size by Country (2024-2034)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Country (2024-2034)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Long-Acting Schizophrenia Drug Market Dynamics
11.1 Long-Acting Schizophrenia Drug Industry Trends
11.2 Long-Acting Schizophrenia Drug Market Drivers
11.3 Long-Acting Schizophrenia Drug Market Challenges
11.4 Long-Acting Schizophrenia Drug Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Long-Acting Schizophrenia Drug Market Size (US$ Million) Comparison by Region 2024 VS 2022 VS 2034
Table 2. Global Long-Acting Schizophrenia Drug Market Size by Region (2024-2024) & (US$ Million)
Table 3. Global Long-Acting Schizophrenia Drug Market Size Share by Region (2024-2024)
Table 4. Global Long-Acting Schizophrenia Drug Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 5. Global Long-Acting Schizophrenia Drug Forecasted Market Size Share by Region (2024-2034)
Table 6. Global Long-Acting Schizophrenia Drug Market Size (US$ Million) by Type: 2024 VS 2022 VS 2034
Table 7. Global Long-Acting Schizophrenia Drug Market Size by Type (2024-2024) & (US$ Million)
Table 8. Global Long-Acting Schizophrenia Drug Revenue Market Share by Type (2024-2024)
Table 9. Global Long-Acting Schizophrenia Drug Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 10. Global Long-Acting Schizophrenia Drug Revenue Market Share by Type (2024-2034)
Table 11. North America Long-Acting Schizophrenia Drug Revenue by Type (2024-2024) & (US$ Million)
Table 12. North America Long-Acting Schizophrenia Drug Revenue by Type (2024-2034) & (US$ Million)
Table 13. Europe Long-Acting Schizophrenia Drug Revenue by Type (2024-2024) & (US$ Million)
Table 14. Europe Long-Acting Schizophrenia Drug Revenue by Type (2024-2034) & (US$ Million)
Table 15. Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Type (2024-2024) & (US$ Million)
Table 16. Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Type (2024-2034) & (US$ Million)
Table 17. Latin America Long-Acting Schizophrenia Drug Revenue by Type (2024-2024) & (US$ Million)
Table 18. Latin America Long-Acting Schizophrenia Drug Revenue by Type (2024-2034) & (US$ Million)
Table 19. Middle East and Africa Long-Acting Schizophrenia Drug Revenue by Type (2024-2024) & (US$ Million)
Table 20. Middle East and Africa Long-Acting Schizophrenia Drug Revenue by Type (2024-2034) & (US$ Million)
Table 21. Global Long-Acting Schizophrenia Drug Market Size (US$ Million) by Application: 2024 VS 2022 VS 2034
Table 22. Global Long-Acting Schizophrenia Drug Market Size by Application (2024-2024) & (US$ Million)
Table 23. Global Long-Acting Schizophrenia Drug Revenue Market Share by Application (2024-2024)
Table 24. Global Long-Acting Schizophrenia Drug Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 25. Global Long-Acting Schizophrenia Drug Revenue Market Share by Application (2024-2034)
Table 26. North America Long-Acting Schizophrenia Drug Revenue by Application (2024-2024) & (US$ Million)
Table 27. North America Long-Acting Schizophrenia Drug Revenue by Application (2024-2034) & (US$ Million)
Table 28. Europe Long-Acting Schizophrenia Drug Revenue by Application (2024-2024) & (US$ Million)
Table 29. Europe Long-Acting Schizophrenia Drug Revenue by Application (2024-2034) & (US$ Million)
Table 30. Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Application (2024-2024) & (US$ Million)
Table 31. Asia-Pacific Long-Acting Schizophrenia Drug Revenue by Application (2024-2034) & (US$ Million)
Table 32. Latin America Long-Acting Schizophrenia Drug Revenue by Application (2024-2024) & (US$ Million)
Table 33. Latin America Long-Acting Schizophrenia Drug Revenue by Application (2024-2034) & (US$ Million)
Table 34. Middle East and Africa Long-Acting Schizophrenia Drug Revenue by Application (2024-2024) & (US$ Million)
Table 35. Middle East and Africa Long-Acting Schizophrenia Drug Revenue by Application (2024-2034) & (US$ Million)
Table 36. Global Long-Acting Schizophrenia Drug Revenue (US$ Million) by Players (2024-2024)
Table 37. Global Long-Acting Schizophrenia Drug Revenue Market Share by Players (2024-2024)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Long-Acting Schizophrenia Drug as of 2022)
Table 39. Date of Key Players Enter into Long-Acting Schizophrenia Drug Market
Table 40. Global Long-Acting Schizophrenia Drug Key Players Headquarters and Area Served
Table 41. Long-Acting Schizophrenia Drug Product Solution and Service
Table 42. Global Long-Acting Schizophrenia Drug Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Johnson & Johnson Basic Information List
Table 45. Johnson & Johnson Description and Business Overview
Table 46. Johnson & Johnson Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 47. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Johnson & Johnson (2024-2024)
Table 48. Johnson & Johnson Recent Developments
Table 49. Teva Basic Information List
Table 50. Teva Description and Business Overview
Table 51. Teva Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 52. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Teva (2024-2024)
Table 53. Teva Recent Developments
Table 54. Eli Lilly Basic Information List
Table 55. Eli Lilly Description and Business Overview
Table 56. Eli Lilly Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 57. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Eli Lilly (2024-2024)
Table 58. Eli Lilly Recent Developments
Table 59. Bristol Myers Squibb Basic Information List
Table 60. Bristol Myers Squibb Description and Business Overview
Table 61. Bristol Myers Squibb Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 62. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Bristol Myers Squibb (2024-2024)
Table 63. Bristol Myers Squibb Recent Developments
Table 64. AstraZeneca Basic Information List
Table 65. AstraZeneca Description and Business Overview
Table 66. AstraZeneca Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 67. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of AstraZeneca (2024-2024)
Table 68. AstraZeneca Recent Developments
Table 69. Sumitomo Dainippon Pharma Basic Information List
Table 70. Sumitomo Dainippon Pharma Description and Business Overview
Table 71. Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 72. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Sumitomo Dainippon Pharma (2024-2024)
Table 73. Sumitomo Dainippon Pharma Recent Developments
Table 74. Allergan Basic Information List
Table 75. Allergan Description and Business Overview
Table 76. Allergan Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 77. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Allergan (2024-2024)
Table 78. Allergan Recent Developments
Table 79. Novartis Basic Information List
Table 80. Novartis Description and Business Overview
Table 81. Novartis Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 82. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Novartis (2024-2024)
Table 83. Novartis Recent Developments
Table 84. Cardinal Health Basic Information List
Table 85. Cardinal Health Description and Business Overview
Table 86. Cardinal Health Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 87. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Cardinal Health (2024-2024)
Table 88. Cardinal Health Recent Developments
Table 89. Sun Pharmaceutical Industries Basic Information List
Table 90. Sun Pharmaceutical Industries Description and Business Overview
Table 91. Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 92. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Sun Pharmaceutical Industries (2024-2024)
Table 93. Sun Pharmaceutical Industries Recent Developments
Table 94. GlaxoSmithKline Basic Information List
Table 95. GlaxoSmithKline Description and Business Overview
Table 96. GlaxoSmithKline Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 97. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of GlaxoSmithKline (2024-2024)
Table 98. GlaxoSmithKline Recent Developments
Table 99. Sanis Health Basic Information List
Table 100. Sanis Health Description and Business Overview
Table 101. Sanis Health Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 102. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Sanis Health (2024-2024)
Table 103. Sanis Health Recent Developments
Table 104. Qilu Pharmaceutical Basic Information List
Table 105. Qilu Pharmaceutical Description and Business Overview
Table 106. Qilu Pharmaceutical Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 107. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Qilu Pharmaceutical (2024-2024)
Table 108. Qilu Pharmaceutical Recent Developments
Table 109. Otsuka Pharmaceutical Basic Information List
Table 110. Otsuka Pharmaceutical Description and Business Overview
Table 111. Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 112. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Otsuka Pharmaceutical (2024-2024)
Table 113. Otsuka Pharmaceutical Recent Developments
Table 114. Vanda Pharmaceuticals Basic Information List
Table 115. Vanda Pharmaceuticals Description and Business Overview
Table 116. Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 117. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Vanda Pharmaceuticals (2024-2024)
Table 118. Vanda Pharmaceuticals Recent Developments
Table 119. H.Lundbeck Basic Information List
Table 120. H.Lundbeck Description and Business Overview
Table 121. H.Lundbeck Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 122. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of H.Lundbeck (2024-2024)
Table 123. H.Lundbeck Recent Developments
Table 124. Organon Basic Information List
Table 125. Organon Description and Business Overview
Table 126. Organon Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 127. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Organon (2024-2024)
Table 128. Organon Recent Developments
Table 129. Hansoh Basic Information List
Table 130. Hansoh Description and Business Overview
Table 131. Hansoh Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 132. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Hansoh (2024-2024)
Table 133. Hansoh Recent Developments
Table 134. Hengrui Basic Information List
Table 135. Hengrui Description and Business Overview
Table 136. Hengrui Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 137. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Hengrui (2024-2024)
Table 138. Hengrui Recent Developments
Table 139. Nhwa Group Basic Information List
Table 140. Nhwa Group Description and Business Overview
Table 141. Nhwa Group Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 142. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Nhwa Group (2024-2024)
Table 143. Nhwa Group Recent Developments
Table 144. Yangtze River Pharmaceutical Group Basic Information List
Table 145. Yangtze River Pharmaceutical Group Description and Business Overview
Table 146. Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Products, Services and Solutions
Table 147. Revenue (US$ Million) in Long-Acting Schizophrenia Drug Business of Yangtze River Pharmaceutical Group (2024-2024)
Table 148. Yangtze River Pharmaceutical Group Recent Developments
Table 149. North America Long-Acting Schizophrenia Drug Market Size by Country (2024-2024) & (US$ Million)
Table 150. North America Long-Acting Schizophrenia Drug Market Size by Country (2024-2034) & (US$ Million)
Table 151. Europe Long-Acting Schizophrenia Drug Market Size by Country (2024-2024) & (US$ Million)
Table 152. Europe Long-Acting Schizophrenia Drug Market Size by Country (2024-2034) & (US$ Million)
Table 153. Asia-Pacific Long-Acting Schizophrenia Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 154. Asia-Pacific Long-Acting Schizophrenia Drug Market Size by Region (2024-2024) & (US$ Million)
Table 155. Asia-Pacific Long-Acting Schizophrenia Drug Market Size by Region (2024-2034) & (US$ Million)
Table 156. Asia-Pacific Long-Acting Schizophrenia Drug Market Share by Region (2024-2024)
Table 157. Asia-Pacific Long-Acting Schizophrenia Drug Market Share by Region (2024-2034)
Table 158. Latin America Long-Acting Schizophrenia Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 159. Latin America Long-Acting Schizophrenia Drug Market Size by Country (2024-2024) & (US$ Million)
Table 160. Latin America Long-Acting Schizophrenia Drug Market Size by Country (2024-2034) & (US$ Million)
Table 161. Middle East & Africa Long-Acting Schizophrenia Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 162. Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Country (2024-2024) & (US$ Million)
Table 163. Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Country (2024-2034) & (US$ Million)
Table 164. Long-Acting Schizophrenia Drug Market Trends
Table 165. Long-Acting Schizophrenia Drug Market Drivers
Table 166. Long-Acting Schizophrenia Drug Market Challenges
Table 167. Long-Acting Schizophrenia Drug Market Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Long-Acting Schizophrenia Drug Market Size Year-over-Year 2024-2034 & (US$ Million)
Figure 2. Global Long-Acting Schizophrenia Drug Market Size (US$ Million), 2024 VS 2022 VS 2034
Figure 3. Global Long-Acting Schizophrenia Drug Market Share by Regions: 2022 VS 2034
Figure 4. Global Long-Acting Schizophrenia Drug Forecasted Market Size Share by Region (2024-2034)
Figure 5. North America Long-Acting Schizophrenia Drug Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 6. Europe Long-Acting Schizophrenia Drug Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 7. Asia-Pacific Long-Acting Schizophrenia Drug Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 8. Latin America Long-Acting Schizophrenia Drug Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 9. Middle East & Africa Long-Acting Schizophrenia Drug Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 10. Product Picture of Oral
Figure 11. Global Oral Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 12. Product Picture of Injection
Figure 13. Global Injection Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 14. Global Long-Acting Schizophrenia Drug Market Size Share by Type: 2022 & 2034
Figure 15. North America Long-Acting Schizophrenia Drug Revenue Market Share by Type (2024-2034)
Figure 16. Europe Long-Acting Schizophrenia Drug Revenue Market Share by Type (2024-2034)
Figure 17. Asia-Pacific Long-Acting Schizophrenia Drug Revenue Market Share by Type (2024-2034)
Figure 18. Latin America Long-Acting Schizophrenia Drug Revenue Market Share by Type (2024-2034)
Figure 19. Middle East and Africa Long-Acting Schizophrenia Drug Revenue Market Share by Type (2024-2034)
Figure 20. Hospital Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 21. Pharmacies Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 22. Other Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 23. Global Long-Acting Schizophrenia Drug Market Size Share by Application: 2022 & 2034
Figure 24. North America Long-Acting Schizophrenia Drug Revenue Market Share by Application (2024-2034)
Figure 25. Europe Long-Acting Schizophrenia Drug Revenue Market Share by Application (2024-2034)
Figure 26. Asia-Pacific Long-Acting Schizophrenia Drug Revenue Market Share by Application (2024-2034)
Figure 27. Latin America Long-Acting Schizophrenia Drug Revenue Market Share by Application (2024-2034)
Figure 28. Middle East and Africa Long-Acting Schizophrenia Drug Revenue Market Share by Application (2024-2034)
Figure 29. Long-Acting Schizophrenia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 30. Global Top 5 and Top 10 Players Long-Acting Schizophrenia Drug Market Share in 2022
Figure 31. North America Long-Acting Schizophrenia Drug Market Share by Country (2024-2034)
Figure 32. United States Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 33. Canada Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 34. Germany Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 35. France Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 36. U.K. Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 37. Italy Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 38. Russia Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 39. Nordic Countries Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 40. Asia-Pacific Long-Acting Schizophrenia Drug Market Share by Region (2024-2034)
Figure 41. China Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 42. Japan Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 43. South Korea Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 44. Southeast Asia Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 45. India Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 46. Australia Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 47. Latin America Long-Acting Schizophrenia Drug Market Share by Country (2024-2034)
Figure 48. Mexico Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 49. Brazil Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 50. Middle East & Africa Long-Acting Schizophrenia Drug Market Share by Country (2024-2034)
Figure 51. Turkey Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 52. Saudi Arabia Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 53. UAE Long-Acting Schizophrenia Drug Market Size (2024-2034) & (US$ Million)
Figure 54. Bottom-up and Top-down Approaches for This Report